MediWound (NASDAQ:MDWD) Director Acquires $49,907.07 in Stock

MediWound Ltd. (NASDAQ:MDWD) Director David Morton Fox purchased 3,537 shares of MediWound stock in a transaction dated Monday, June 1st. The stock was bought at an average price of $14.11 per share, with a total value of $49,907.07. Following the completion of the purchase, the director directly owned 22,283 shares of the company’s stock, valued at approximately $314,413.13. This trade represents a 18.87% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

MediWound Stock Down 3.6%

Shares of MediWound stock opened at $13.82 on Tuesday. MediWound Ltd. has a twelve month low of $13.61 and a twelve month high of $22.50. The company’s 50 day moving average is $16.56 and its 200 day moving average is $17.40. The company has a market cap of $177.59 million, a price-to-earnings ratio of -6.12 and a beta of 0.16.

MediWound (NASDAQ:MDWD) last announced its earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.42. The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $3.37 million. MediWound had a negative net margin of 180.30% and a negative return on equity of 67.22%. During the same period in the previous year, the business earned ($0.07) EPS. Sell-side analysts expect that MediWound Ltd. will post -2.49 EPS for the current fiscal year.

Hedge Funds Weigh In On MediWound

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rosalind Advisors Inc. increased its holdings in MediWound by 84.0% in the 3rd quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock valued at $13,498,000 after acquiring an additional 341,993 shares during the last quarter. Kotler Kevin purchased a new position in shares of MediWound during the fourth quarter valued at about $6,225,000. Sphera Funds Management LTD. increased its holdings in shares of MediWound by 24.3% in the fourth quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock worth $4,252,000 after purchasing an additional 45,077 shares during the last quarter. Silverberg Bernstein Capital Management LLC increased its holdings in shares of MediWound by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 200,005 shares of the biopharmaceutical company’s stock worth $3,222,000 after purchasing an additional 16,081 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of MediWound by 355.6% in the third quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock worth $3,160,000 after buying an additional 136,884 shares in the last quarter. Institutional investors own 46.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Oppenheimer reissued an “outperform” rating and issued a $32.00 target price (down from $33.00) on shares of MediWound in a report on Wednesday, May 27th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of MediWound in a research report on Thursday, May 28th. Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a report on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $34.00.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.